Aytu BioPharma Future Growth
Future criteria checks 3/6
Aytu BioPharma is forecast to grow earnings and revenue by 67.4% and 2.2% per annum respectively while EPS is expected to grow by 69.6% per annum.
Key information
67.4%
Earnings growth rate
69.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 2.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Feb 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | 125 | 8 | 12 | 12 | 1 |
| 6/30/2024 | 124 | -1 | 7 | 6 | 2 |
| 6/30/2023 | 108 | -14 | N/A | -17 | 1 |
| 12/31/2022 | 106 | -78 | -28 | -28 | N/A |
| 9/30/2022 | 102 | -83 | -34 | -34 | N/A |
| 6/30/2022 | 97 | -110 | -29 | -29 | N/A |
| 3/31/2022 | 93 | -111 | -30 | -28 | N/A |
| 12/31/2021 | 82 | -84 | -30 | -28 | N/A |
| 9/30/2021 | 74 | -82 | -24 | -22 | N/A |
| 6/30/2021 | 66 | -58 | -28 | -26 | N/A |
| 3/31/2021 | 57 | -42 | -27 | -27 | N/A |
| 12/31/2020 | 52 | -22 | -30 | -30 | N/A |
| 9/30/2020 | 40 | -13 | -33 | -33 | N/A |
| 6/30/2020 | 28 | -14 | -28 | -28 | N/A |
| 3/31/2020 | 14 | -25 | -24 | -24 | N/A |
| 12/31/2019 | 9 | -24 | -16 | -16 | N/A |
| 9/30/2019 | 7 | -29 | -14 | -14 | N/A |
| 6/30/2019 | 7 | -27 | -14 | -14 | N/A |
| 3/31/2019 | 7 | -12 | -16 | -15 | N/A |
| 12/31/2018 | 5 | -10 | -17 | -16 | N/A |
| 9/30/2018 | 4 | -9 | -15 | -14 | N/A |
| 6/30/2018 | 4 | -10 | -16 | -16 | N/A |
| 3/31/2018 | 4 | -17 | -15 | -15 | N/A |
| 12/31/2017 | 4 | -20 | -17 | -13 | N/A |
| 9/30/2017 | 4 | -21 | -19 | -13 | N/A |
| 6/30/2017 | 3 | -23 | -20 | -14 | N/A |
| 3/31/2017 | 3 | -31 | -21 | -13 | N/A |
| 12/31/2016 | 3 | -33 | -17 | -13 | N/A |
| 9/30/2016 | 3 | -32 | N/A | -14 | N/A |
| 6/30/2016 | 3 | -28 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AY20 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: AY20 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AY20 is expected to become profitable in the next 3 years.
Revenue vs Market: AY20's revenue (2.2% per year) is forecast to grow slower than the German market (4.6% per year).
High Growth Revenue: AY20's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AY20's Return on Equity is forecast to be high in 3 years time